U-Blot® IL-6 hIgG1 Reference Antibody (Siltubio)

Background:Interleukin-6(IL-6) is a classic Proinflammatory cytokine. The gene for IL-6 is located on chromosome 7 and encodes a precursor protein that is spliced and glycated to produce secreted IL-6. IL-6 binds to membrane-bound IL-6R (mbIL-6R) , recruits GP130, and activates pathways such as Jak/STAT3, MAPK, PI3K/AKT. Abnormal IL-6 signaling is closely related to the pathological process of a variety of diseases, including autoimmune diseases, infectious inflammation, metabolic syndrome, and the tumor-associated inflammatory microenvironment, which may contribute to the pathogenesis of inflammatory diseases, is a key drug target for multiple targeted therapies, such as IL-6/IL-6R inhibitors. Siltuximab is a humanized monoclonal antibody that directly neutralizes IL-6, blocks IL-6IL-6R signaling, and inhibits the inflammatory cascade of classical and trans-signaling. By directly neutralizing IL-6, the activation intensity of the two signaling pathways was reduced, and then the expression of downstream transcription factors (such as phosphorylation and nuclear translocation of STAT3) and a variety of inflammation-related genes were inhibited.